Kintara Stock Analysis


USD 8.82  2.12  31.64%   

The current price rise of Kintara Therapeutics may raise some interest from investors. The stock closed today at a share price of 8.82 on 1,997,132 in trading volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in January. The stock standard deviation of daily returns for 90 days investing horizon is currently 14.77. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Kintara Therapeutics partners.
Please see Correlation Analysis.
The Kintara Therapeutics stock analysis report makes it easy to digest most publicly released information about Kintara Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Kintara Stock analysis module also helps to analyze the Kintara Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Kintara Stock Analysis Notes

The company recorded a loss per share of 0.64. Kintara Therapeutics last dividend was issued on the 8th of May 2019. The entity had 1:50 split on the 14th of November 2022. Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California. Kintara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To find out more about Kintara Therapeutics contact BBA CPA at 858 350 4364 or learn more at

Kintara Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Kintara Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Kintara Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Kintara Therapeutics is way too risky over 90 days horizon
Kintara Therapeutics appears to be risky and price may revert if volatility continues
Net Loss for the year was (22.66 M) with profit before overhead, payroll, taxes, and interest of 0.
Kintara Therapeutics currently holds about 11.78 M in cash with (20.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15.

Kintara Therapeutics Upcoming and Recent Events

Earnings reports are used by Kintara Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kintara Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report11th of February 2022
Next Financial Report13th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End5th of October 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Kintara Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Kintara Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Kintara Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Kintara Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
3rd of August 2022
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
22nd of June 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
16th of June 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
3rd of June 2022
Financial Statements and Exhibits. Other Events. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
24th of May 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
13th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
20th of April 2022
Unclassified Corporate Event
18th of April 2022
Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year

Kintara Market Capitalization

The company currently falls under 'Nano-Cap' category with current market capitalization of 9.62 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kintara Therapeutics's market, we take the total number of its shares issued and multiply it by Kintara Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (0.7509) % which means that it has lost $0.7509 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (1.4795) %, meaning that it created substantial loss on money invested by shareholders. Kintara Therapeutics management efficiency ratios could be used to measure how well kintara therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 1st of December, Kintara Therapeutics secures the Downside Deviation of 7.53, mean deviation of 5.89, and Risk Adjusted Performance of 0.037. Kintara Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Kintara Therapeutics, which can be compared to its peers in the industry. Please verify Kintara Therapeutics treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Kintara Therapeutics is priced some-what accurately, providing market reflects its recent price of 8.82 per share. Given that Kintara Therapeutics has jensen alpha of 0.1418, we recommend you to check Kintara Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.

Kintara Therapeutics Price Movement Analysis

The output start index for this execution was eighteen with a total number of output elements of fourty-three. Kintara Therapeutics Triple Exponential Moving Average indicator shows smoothing effect of Kintara Therapeutics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.

Kintara Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kintara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kintara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kintara Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Kintara Therapeutics Predictive Daily Indicators

Kintara Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kintara Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Kintara Therapeutics Forecast Models

Kintara Therapeutics time-series forecasting models is one of many Kintara Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kintara Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Kintara Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kintara Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kintara shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Kintara Therapeutics. By using and applying Kintara Stock analysis, traders can create a robust methodology for identifying Kintara entry and exit points for their positions.
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California. Kintara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Current Kintara Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kintara analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kintara analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
4.75Strong Buy4Odds
Kintara Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Kintara analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Kintara stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Kintara Therapeutics, talking to its executives and customers, or listening to Kintara conference calls.
Kintara Analyst Advice Details

Kintara Stock Analysis Indicators

Kintara Therapeutics stock analysis indicators help investors evaluate how Kintara Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kintara Therapeutics shares will generate the highest return on investment. By understating and applying Kintara Therapeutics stock analysis, traders can identify Kintara Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow10537000.00
Logo U R LimglogosUSKTRA.png
Common Stock Shares Outstanding974040.00
Total Stockholder Equity11795000.00
Property Plant And Equipment Net90000.00
Retained Earnings-136356000.00
Cash And Short Term Investments11780000.00
Accounts Payable3269000.00
Net Debt-11780000.00
50 Day M A5.2003
Total Current Liabilities3990000.00
Currency CodeUSD
Other Operating Expenses22682000.00
Non Current Assets Total2690000.00
Non Currrent Assets Other2600000.00
Please see Correlation Analysis. You can also try Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for analysis

When running Kintara Therapeutics price analysis, check to measure Kintara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kintara Therapeutics is operating at the current time. Most of Kintara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kintara Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kintara Therapeutics' price. Additionally, you may evaluate how the addition of Kintara Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is Kintara Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kintara Therapeutics. If investors know Kintara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kintara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
9.6 M
Return On Assets
Return On Equity
The market value of Kintara Therapeutics is measured differently than its book value, which is the value of Kintara that is recorded on the company's balance sheet. Investors also form their own opinion of Kintara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kintara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kintara Therapeutics' market value can be influenced by many factors that don't directly affect Kintara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kintara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Kintara Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kintara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.